Innovative Industrial Properties (IIPR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
24 Feb, 2026Executive summary
Diversified REIT with $2.5B invested capital, operating across cannabis and life sciences in 19 U.S. states with 111 properties and over 35 tenants.
2025 marked by disciplined execution, strong balance sheet, and strategic repositioning for long-term growth.
Achieved total revenues of $266.0 million and net income attributable to common stockholders of $114.4 million, or $3.93 per diluted share for 2025.
Returned over $1.1 billion to shareholders through dividends since inception, with $7.60 per share declared for 2025.
Strategic $270 million investment in life sciences via IQHQ, enhancing sector diversification and expected to be accretive to AFFO per share.
Financial highlights
Total revenues for 2025 were $266 million; AFFO reached $205.4 million, or $7.24 per diluted share.
Q4 2025 revenues were $66.7 million; AFFO was $53.3 million ($1.88/share), with net income of $30.7 million.
AFFO per share (annualized Q4 2025): $7.52; dividends per share (annualized Q4 2025): $7.60.
Exited 2025 with liquidity exceeding $105 million, including cash and credit facilities.
Gross debt: $393.7 million; preferred equity: $50.5 million; debt to total gross assets: 14%.
Outlook and guidance
Raised over $40 million of preferred stock in early 2026 at a yield just over 9.5%.
Committed to funding up to an additional $120 million in preferred equity to IQHQ through 2027.
U.S. legal cannabis market projected to grow at 7% CAGR from 2024–2029, reaching $44 billion by 2029.
Life sciences R&D expenditures have grown 7% annually from 2014–2024; sector expected to continue strong growth.
Expect continued strong leasing activity and resolution of non-performing assets to drive earnings upside in future quarters.
Latest events from Innovative Industrial Properties
- Q2 revenue up 4% to $79.8M, AFFO $2.29/share, 95.6% leased, and dividend up 4.4%.IIPR
Q2 20242 Feb 2026 - Q3 2024 revenue was $76.5M, AFFO $64.3M, and portfolio was 95.7% leased.IIPR
Q3 202415 Jan 2026 - 2024 revenue steady at $308.5M; strong liquidity, high occupancy, and PharmaCann lease resolution.IIPR
Q4 202423 Dec 2025 - 2024 saw record revenue, strong governance, and enhanced ESG and compensation practices.IIPR
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all.IIPR
Proxy Filing1 Dec 2025 - Q1 2025 revenue and net income fell on tenant defaults, but liquidity and leasing remain strong.IIPR
Q1 202524 Nov 2025 - Q2 2025 revenue and AFFO fell sharply, but liquidity is strong and IQHQ investment boosts outlook.IIPR
Q2 202523 Nov 2025 - Q3 2025 revenue fell 15% to $64.7M as tenant defaults hit, but life sciences diversification advanced.IIPR
Q3 202513 Nov 2025 - Diversified cannabis real estate portfolio drives growth and strong shareholder returns.IIPR
Investor Presentation14 Oct 2025